highly significantp = 0.0014
Also, the main hospital, which had maximum experience with the use of CP, showed a highly significant mortality benefit in severe COVID-19 (20.5% vs 34.9%; p = 0.0014; OR = 0.48, 95% CI: 0.29–0.80).
Also, the main hospital, which had maximum experience with the use of CP, showed a highly significant mortality benefit in severe COVID-19 (20.5% vs 34.9%; p = 0.0014; OR = 0.48, 95% CI: 0.29–0.80).
We observed a similar reduction in mortality in patients with 2 comorbidities (35.1% vs 49.2%) but this did not reach statistical significance (p = 0.099; OR = 0.56, 95% CI: 0.28–1.12).